Phase 3 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with DCIS (a type of non-invasive breast condition) of any grade or size who are planning to have a full breast removal (mastectomy)
- People planning a risk-reducing mastectomy where sentinel lymph node surgery would normally be recommended as part of that procedure, either as standard practice at the treating hospital or based on an individual recommendation from their medical team
- People with a pre-surgery diagnosis of DCIS grade 3 of any size, or DCIS grade 2 measuring 20mm or larger on mammogram, who are planning breast-conserving surgery
- People with a pre-surgery diagnosis of DCIS detected on a core biopsy, where a lump can be felt during physical examination or is visible on imaging
- People with a pre-surgery diagnosis of DCIS where there is a suspicion of very early invasion into surrounding tissue, detected on core biopsy
- People with an imaging finding (mammogram, ultrasound, or MRI) that is suspicious for breast cancer (rated BIRADS 4 or 5) who are planned for a diagnostic surgical removal using breast-conserving surgery, with no confirmed diagnosis of invasive cancer
- People with a pre-surgery diagnosis of DCIS of any grade or size who are planned for a complex breast reshaping surgical procedure
- People with a pre-surgery diagnosis of DCIS of any grade or size where the planned surgery may make it harder to perform sentinel lymph node surgery in the future — for example, when the affected area is in the upper outer part of the breast, near the armpit, or when nipple removal is planned (confirm with trial site for other situations)
- People in any of the above categories whose pre-surgery diagnosis is pleomorphic lobular cancer in situ (pLCIS), classic lobular neoplasia (LN), or atypical ductal hyperplasia (ADH), rather than DCIS
Who may not be able to join:
- People who have a known intolerance or allergic reaction to iron, dextran compounds, or a substance called SPIO (a type of iron-based imaging agent used in the trial)
- People who have a medical condition involving an excess of iron in the body (iron overload disease)
- People who are currently under legal guardianship or whose personal freedom is restricted (confirm with trial site)
- People who are pregnant or currently breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Andreas Karakatsanis, PhD, Uppsala University
Phone: +46765864826
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
d-SLND detection rate; l-SLND detection rate; Nodal concordance
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.